News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

OmniLytics Enters Collaboration with Elanco


3/11/2008 9:39:28 AM

SALT LAKE CITY--(BUSINESS WIRE)--OmniLytics, Inc. of Salt Lake City, UT today announced that it has entered into a collaborative research and license agreement with Elanco, a division of Eli Lilly and Company (NYSE: LLY), encompassing a series of products for the treatment of food-borne bacterial pathogens using OmniLytics’ bacteriophage (“phage”) technology.

Read at BioSpace.com


comments powered by Disqus
OmniLytics
Elanco
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES